Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADXS-503 Alone and in Combination With Pembrolizumab in Metastatic NSCLC
NCT03847519Phase 2Completed
- Sponsor
- Advaxis, Inc.
- Start
- Feb 2019
- Primary completion
- Feb 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ost-503 in non-small cell lung cancer (NSCLC), sponsored by Advaxis, Inc.. Started Feb 2019; status: completed.
02
Drugs
ost-503
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03847519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03847519.